Law Firm Announces Investigation of Companies
Acadia Pharmaceuticals Inc. Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board of Acadia Pharmaceuticals Inc. (ACAD). Specifically, on March 11, 2015, ACAD delayed the submission of a U.S. application to market its lead drug, nuplazid, and that its chief executive was retiring. For more information about our investigation, please